Summary
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
History
Founded in 2009 and headquartered in Boulder, Colorado, Biodesix has established itself at the nexus of diagnostics, technology and therapeutics through the commercialization of novel multi-omics tests and Artificial Intelligence (AI) based clinical decision support. In addition to developing novel diagnostics and the BioPortal® phenotypic interpretation platform, Biodesix combines data-driven diagnostics with advanced technologies such as AI, machine learning, and computer simulation to develop unique approaches to patient management.
Mission
Our mission is to use data-driven diagnostics and AI-based clinical decision support to enable precision medicine. We strive to create revolutionary approaches to patient care that are accessible, personalized and comprehensive.
Vision
Our vision is to revolutionize precision medicine by delivering life changing decisions to physicians and patients, enabling them to make health care decisions with confidence.
Key Team
Dr. Heinrich Röder (Founder & CTO)
Dr. Robert W. Georgantas III, Ph.D. (Chief Scientific Officer)
Dr. Paul J. Beresford (Chief Bus. Officer)
Mr. Jeffrey A. Bojar (VP of Legal and Regulatory Affairs)
Mr. Matt Stauffer (VP of Sales)
Dr. Gary Anthony Pestano Ph.D. (Chief Devel. Officer)
Ms. Bobbi Coffin (Chief Growth Officer)
Recognition and Awards
Biodesix has been consistently recognized for its innovation, technology, and data analytics. The company was named the Small Business of the Year by the Boulder Chamber of Commerce, winner of the Rice Alliance’s 2019 Texas Life Science Venture Forum Competition, finalist for the 2017 Colorado Companies to Watch and winner of the Dave Culver Entrepreneurial Award from the University of Colorado's Leeds School of Business
References
United States 